27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
Gamida Cell (NASDAQ:GMA) shares are trading higher Wednesday after the company reported the results of the efficacy and safety for its Phase 3 study of Omidubicel at the TCT meetings of ASTCT and CIBMTR.
Gamida Cell Ltd is a biopharmaceutical company involved in developing advanced cell therapies with the potential to cure cancer and rare, serious hematologic diseases. The company's product includes NiCord that is a cell therapy based on NAM-expanded cord blood designed to enhance and expand the life-saving benefits of hematopoietic stem cell transplant.
Gamida Cell stock was up 24.29% at $12.29. The stock has a 52-week high of $15 and a 52-week low of $2.60
27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!